BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25130430)

  • 1. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis.
    Trenova AG; Slavov GS; Manova MG; Kostadinova II
    Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up.
    Flechter S; Vardi J; Pollak L; Rabey JM
    J Neurol Sci; 2002 May; 197(1-2):51-5. PubMed ID: 11997066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
    Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
    Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates.
    Brown MG; Murray TJ; Sketris IS; Fisk JD; LeBlanc JC; Schwartz CE; Skedgel C
    Int J Technol Assess Health Care; 2000; 16(3):751-67. PubMed ID: 11028131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines.
    Sega S; Wraber B; Mesec A; Horvat A; Ihan A
    Clin Neurol Neurosurg; 2004 Jun; 106(3):255-8. PubMed ID: 15177779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins as immunomodulators: comparison with interferon-beta 1b in MS.
    Neuhaus O; Strasser-Fuchs S; Fazekas F; Kieseier BC; Niederwieser G; Hartung HP; Archelos JJ
    Neurology; 2002 Oct; 59(7):990-7. PubMed ID: 12370451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b.
    Iarlori C; Reale M; Lugaresi A; De Luca G; Bonanni L; Di Iorio A; Feliciani C; Conti P; Gambi D
    J Neuroimmunol; 2000 Jul; 107(1):100-7. PubMed ID: 10808056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell interferon gamma receptor binding in interferon beta-1b-treated patients with multiple sclerosis.
    Bongioanni P; Lombardo F; Moscato G; Mosti S; Meucci G
    Arch Neurol; 1999 Feb; 56(2):217-22. PubMed ID: 10025427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.
    Paolillo A; Pozzilli C; Giugni E; Tomassini V; Gasperini C; Fiorelli M; Mainero C; Horsfield M; Galgani S; Bastianello S; Buttinelli C
    Eur J Neurol; 2002 Nov; 9(6):645-55. PubMed ID: 12453081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients.
    Milanese C; La Mantia L; Palumbo R; Martinelli V; Murialdo A; Zaffaroni M; Caputo D; Capra R; Bergamaschi R;
    J Neurol Neurosurg Psychiatry; 2003 Dec; 74(12):1689-92. PubMed ID: 14638892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon beta-1b treatment in patients with relapsing--remitting multiple sclerosis under a standardized protocol in Spain.
    Arbizu T; Alvarez-Cermeño JC; Decap G; Fernández O; Uría DF; García Merino A; Izquierdo G; Montalbán X
    Acta Neurol Scand; 2000 Oct; 102(4):209-17. PubMed ID: 11071104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon beta treatment in relapsing-remitting multiple sclerosis: a post-marketing study in Lombardia, Italy. Multiple Sclerosis Centers of Lombardia, Italy.
    Milanese C; La Mantia L; Palumbo R
    Ital J Neurol Sci; 1999 Oct; 20(5):297-302. PubMed ID: 10933438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
    Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
    Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients.
    Nguyen LT; Ramanathan M; Weinstock-Guttman B; Baier M; Brownscheidle C; Jacobs LD
    J Neurol Sci; 2003 May; 209(1-2):93-9. PubMed ID: 12686409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis.
    Kivisäkk P; Alm GV; Fredrikson S; Link H
    Eur J Neurol; 2000 Jan; 7(1):27-34. PubMed ID: 10809912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients.
    Ferrarini AM; Sivieri S; Buttarello M; Facchinetti A; Perini P; Gallo P
    Mult Scler; 1998 Jun; 4(3):174-7. PubMed ID: 9762669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis.
    Qu ZX; Pliskin N; Jensen MW; White D; Arnason BG
    Arch Neurol; 2001 Jan; 58(1):87-90. PubMed ID: 11176940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.